Beyond the platelet count: Heparin antibodies as independent risk predictors

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 900-906

  Stribling, W Kyle ^a   Slaughter, Thomas F ^a   Houle, Timothy T ^a   Sane, David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ANTIBODY RESPONSE; ARTERY THROMBOSIS; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; IMMUNOGENICITY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

ANTIBODIES; ANTIBODY FORMATION; CARDIOVASCULAR DISEASES; HEPARIN; HUMANS; PLATELET ACTIVATION; PLATELET COUNT; PLATELET FACTOR 4; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 34249320140     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.013     Document Type: Review

References (44)

1. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 126 (2004) 311S-337S
2. Walenga J.M., Jeske W.P., Prechel M.M., et al. Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin Thromb Hemost 30 Suppl 1 (2004) 57-67
3. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
4. Lubenow N., Kempf R., Eichner A., et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122 (2002) 37-42
5. Francis J.L. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 30 (2004) 359-368
6. Juhl D., Eichler P., Lubenow N., et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 76 (2006) 420-426
7. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. J Lab Clin Med 146 (2005) 341-346
8. Mattioli A.V., Bonetti L., Sternieri S., et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 1 (2000) 39-42
9. Williams R.T., Damaraju L.V., Mascelli M.A., et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107 (2003) 2307-2312
10. Matsuo T., Tomaru T., Kario K., et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 115 (2005) 475-481
11. Gluckman T.J., Segal J.B., Fredde N.L., et al. Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol 95 (2005) 744-747
12. Bennett-Guerrero E., Slaughter T.F., White W.D., et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130 (2005) 1567-1572
13. Hach-Wunderle V., Kainer K., Salzmann G., et al. Heparin-related thrombosis despite normal platelet counts in vascular surgery. Am J Surg 173 (1997) 117-119
14. Peña de la Vega L., Miller R.S., Benda M.M., et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 80 (2005) 995-1000
15. Yu A., Jacobson S., Bygden A., et al. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin Chem Lab Med 40 (2002) 21-26
16. Lindhoff-Last E., Nakov R., Misselwitz F., et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 118 (2002) 1137-1142
17. Calaitges J.G., Liem T.K., Spadone D., et al. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 29 (1999) 779-786
18. Lindhoff-Last E., Eichler P., Stein M., et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 97 (2000) 387-393
19. Warkentin T.E., Levine M.N., Hirsch J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
20. Rauova L., Zhai L., Kowalska A., et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107 (2006) 2346-2353
21. Prechel M.M., McDonald M.K., Jeske W.P., et al. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 3 (2005) 2168-2175
22. Blank M., Shoenfeld Y., Tavor S., et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14 (2002) 121-129
23. Herbert J.M., Savi P., Jeske W.P., et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 80 (1998) 326
24. Amiral J., Wolf M., Fischer A., et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92 (1996) 954-959
25. Lindhoff-Last E., Gerdsen F., Ackermann H., et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 113 (2001) 886-890
26. Pouplard C., Iochmann S., Renard B., et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97 (2001) 3300-3302
27. Khairy M., Lasne D., Amelot A., et al. Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood. Thromb Haemost 92 (2004) 1411-1419
28. Khairy M., Lasne D., Brohard-Bohn B., et al. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 85 (2001) 1090-1096
29. Mascelli M.A., Deliargyris E.N., Damaraju L.V., et al. Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombolysis 18 (2004) 171-175
30. Rossi D., and Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 18 (2000) 217-242
31. Amiral J., Marfaing-Koka A., Wolf M., et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88 (1996) 410-416
32. Matsuo T., Suzuki S., Matsuo M., et al. Preexisting antibodies to platelet factor 4-heparin complexes in patients with acute coronary syndrome who have no history of heparin exposure. Pathophysiol Haemost Thromb 34 (2005) 18-22
33. Reilly M.P., Taylor S.M., Franklin C., et al. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J Thromb Haemost 4 (2006) 2687-2694
34. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 (2006) 759-765
35. Warkentin T.E., and Sheppard J.I. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure [letter]. J Thromb Haemost 4 (2006) 281-282
36. Visentin G.P., Malik M., Cyganiak K.A., et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 128 (1996) 376-383
37. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies in patients undergoing cardiopulmonary bypass surgery. Circulation 95 (1997) 1242-1246
38. Reininger C.B., Greinache A., Graf J., et al. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 81 (1996) 641-649
39. Warkentin T.E., Sheppard J.I., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
40. Warkentin T.E., and Kelton J.G. Interactions of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H. (Ed). Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases (1994), Marcel Dekker, New York 75-127
41. Arnold D.M., and Kelton J.G. Heparin-induced thrombocytopenia: an iceberg rising. Mayo Clin Proc 80 (2005) 988-990
42. Rajagopal V., and Bhatt D.L. Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. J Thromb Haemost 3 (2005) 436-438
43. OASIS-6 Investigators. Effect of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. JAMA 295 (2006) 1519-1530
44. Exaire J.E., Butman S.M., Ebrahimi R., et al. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J (2006) 157-163